Using the tumor proportion score (TPS) ≥ 1% as the cut off to select patients who may benefit from pembrolizumab, the combined results of KEYNOTE-028 and KEYNOTE-158 clinical trials showed 73% of patients were PD-L1 positive with an overall response rate of 10.9% (6, 8). Here, CD274 is linked to neoplasm.